
First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC
The addition of eftilagimod alpha (efti; IMP321) to pembrolizumab (Keytruda) and chemotherapy led to high rates of responses and disease control in the first-line treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung …